Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

21
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
21
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

22
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
22
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

884
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
884
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

33
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
33
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

41
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
41

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Six Years Since Selinexor Approval for Relapsed Multiple Myeloma: What Have We Learned?

Cancer investigation·2026
Same author

The meta-analysis deluge: When synthesis becomes pollution.

European journal of internal medicine·2026
Same author

Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Access to Bispecific Therapies for Multiple Myeloma: An Overview of Barriers and Emerging Solutions.

Clinical lymphoma, myeloma & leukemia·2026
Same author

How I Treat Plasma Cell Leukemia.

Blood·2026
Same author

BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: three approvals, many questions.

The oncologist·2026

Related Experiment Video

Updated: Sep 6, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K

Thromboprophylaxis in multiple myeloma.

Nishanth Thalambedu1, Samer Al Hadidi1

  • 1Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Leukemia & Lymphoma
|June 27, 2022
PubMed
Summary

Multiple myeloma patients face high venous thromboembolism (VTE) risk, especially post-diagnosis. This review guides oncologists on using anticoagulation for VTE prevention, detailing efficacy and risks.

Keywords:
DOACsMultiple myelomaanticoagulationdeep venous thrombosispulmonary embolismvenous thromboembolism

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.1K

Related Experiment Videos

Last Updated: Sep 6, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.1K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Background:

  • Venous thromboembolism (VTE) is a significant complication in multiple myeloma (MM).
  • VTE risk is multifactorial, influenced by patient, disease, and treatment factors.
  • Highest VTE risk occurs within the first year following MM diagnosis, leading to substantial morbidity.

Purpose of the Study:

  • To provide an evidence-based summary for oncologists on VTE prevention in MM.
  • To guide the use of anticoagulation strategies for managing VTE risk.
  • To review anticoagulation efficacy, adverse effects, and current recommendations.

Main Methods:

  • Clinical review of existing literature and evidence.
  • Analysis of pathophysiology of VTE in MM.
  • Evaluation of risk prediction tools and anticoagulant therapies.

Main Results:

  • VTE in MM is linked to patient, disease, and treatment factors.
  • Anticoagulation is a key strategy for VTE prophylaxis.
  • Understanding risk factors and available anticoagulants is crucial for management.

Conclusions:

  • Effective anticoagulation strategies are essential for reducing VTE morbidity in MM patients.
  • Oncologists require guidance on optimal anticoagulation use.
  • Risk stratification and appropriate anticoagulant selection are critical for VTE prevention in MM.